JP4863620B2 - 抹消血単核細胞の培養方法及び該細胞を用いた薬剤組成物 - Google Patents

抹消血単核細胞の培養方法及び該細胞を用いた薬剤組成物 Download PDF

Info

Publication number
JP4863620B2
JP4863620B2 JP2004562241A JP2004562241A JP4863620B2 JP 4863620 B2 JP4863620 B2 JP 4863620B2 JP 2004562241 A JP2004562241 A JP 2004562241A JP 2004562241 A JP2004562241 A JP 2004562241A JP 4863620 B2 JP4863620 B2 JP 4863620B2
Authority
JP
Japan
Prior art keywords
cells
blood
patient
peripheral blood
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004562241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514034A5 (enExample
JP2006514034A (ja
Inventor
ヤング，デマオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2006514034A publication Critical patent/JP2006514034A/ja
Publication of JP2006514034A5 publication Critical patent/JP2006514034A5/ja
Application granted granted Critical
Publication of JP4863620B2 publication Critical patent/JP4863620B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2004562241A 2002-05-29 2003-05-07 抹消血単核細胞の培養方法及び該細胞を用いた薬剤組成物 Expired - Fee Related JP4863620B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/159,148 2002-05-29
US10/159,148 US7048922B2 (en) 2002-05-29 2002-05-29 Stimulation of hematopoiesis by ex vivo activated immune cells
PCT/US2003/014336 WO2004056397A1 (en) 2002-05-29 2003-05-07 Stimulation of hematopoiesis by ex vivo actived immune cells

Publications (3)

Publication Number Publication Date
JP2006514034A JP2006514034A (ja) 2006-04-27
JP2006514034A5 JP2006514034A5 (enExample) 2006-06-22
JP4863620B2 true JP4863620B2 (ja) 2012-01-25

Family

ID=29582827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004562241A Expired - Fee Related JP4863620B2 (ja) 2002-05-29 2003-05-07 抹消血単核細胞の培養方法及び該細胞を用いた薬剤組成物

Country Status (6)

Country Link
US (3) US7048922B2 (enExample)
EP (2) EP1511515B1 (enExample)
JP (1) JP4863620B2 (enExample)
DE (1) DE60325967D1 (enExample)
ES (1) ES2321189T3 (enExample)
WO (1) WO2004056397A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048922B2 (en) * 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
US7332158B2 (en) 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
ATE496118T1 (de) * 2003-07-06 2011-02-15 Roger Williams Medical Ct Verfahren zur herstellung differenzierter hämatopoetischer zellen zur behandlung von zytopenie
JP2008512454A (ja) * 2004-09-10 2008-04-24 ヤング，デマオ 骨髄抑制患者に対する体外活性化細胞療法の構成と応用
US20060057121A1 (en) * 2004-09-10 2006-03-16 Demao Yang Compositions and treatments using ex vivo activated cells for myelosuppressed patients
US20080195007A1 (en) * 2007-02-12 2008-08-14 Yury Podrazhansky Method and device for using vibroacoustic stimulaton to enhance the production of adult stem cells in living organisms
GB0918615D0 (en) * 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US20130071437A1 (en) * 2010-08-06 2013-03-21 Canine-Lab.Inc. Immunological function enhancing agent
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US12458249B2 (en) * 2018-03-29 2025-11-04 Demao Yang Cell therapy for patients
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020649A1 (en) * 1994-01-27 1995-08-03 Cellcor, Inc. Ex vivo activation of immune cells
US5643786A (en) * 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
WO1999047641A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Compositions and methods for gene-based vaccines to provoke t cell responses
JP2002511870A (ja) * 1997-06-30 2002-04-16 アメリカ合衆国 活性化骨髄性樹状細胞表現型の誘導

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US5047421A (en) 1984-01-26 1991-09-10 Oral-D Orally effective ion chelators
US5550161A (en) 1984-01-26 1996-08-27 Oral-D Substituted orally effective ION chelators related to deferoxamine
US5015664A (en) 1984-01-26 1991-05-14 Oral D Orally effective ion chelators related to deferoxamine
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5108760A (en) 1989-07-21 1992-04-28 Terumo Corporation Enhances lak cell activation by treatment of human peripheral blood mononuclear cells with amino acid amides
US5525232A (en) 1990-03-02 1996-06-11 The Liposome Company, Inc. Method for entrapment of cationic species in lemellar vesicles
DK0633929T3 (da) 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5312831A (en) 1993-05-12 1994-05-17 American Cyanamid Company Urethanes and ureas that induce cytokine production
EP0641776A3 (en) 1993-09-08 1997-05-02 Takeda Chemical Industries Ltd Thioglycerol derivatives.
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US6033661A (en) 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6008042A (en) 1996-05-16 1999-12-28 Smithkline Beecham Corporation Interleukin-1 beta converting enzyme like apoptotic protease-7
US6010878A (en) 1996-05-20 2000-01-04 Smithkline Beecham Corporation Interleukin-1 β converting enzyme like apoptotic protease-6
US5968513A (en) 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
WO1998006823A2 (en) 1996-08-14 1998-02-19 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
WO1998026747A2 (en) 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US5932446A (en) 1997-08-18 1999-08-03 Smithkline Beecham Corporation Hmvab41
CA2346769C (en) 1997-10-10 2004-09-14 The Regents Of The University Of California Implants comprising combinations of allogeneic cells for use in cancer treatment
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
WO2001034788A1 (en) 1999-11-10 2001-05-17 Yoreh Biotechnologies Ltd. In-vitro assay for assessment of cytotoxicity of a candidate agent
WO2001062092A1 (en) 2000-02-25 2001-08-30 Thomas Jefferson University Formulations and methods for using the same to elicit an immune response
AU2002218019A1 (en) 2000-11-03 2002-05-15 Nexell Therapeutics Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7332158B2 (en) 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
US7048922B2 (en) 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020649A1 (en) * 1994-01-27 1995-08-03 Cellcor, Inc. Ex vivo activation of immune cells
US5643786A (en) * 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
JP2002511870A (ja) * 1997-06-30 2002-04-16 アメリカ合衆国 活性化骨髄性樹状細胞表現型の誘導
WO1999047641A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Compositions and methods for gene-based vaccines to provoke t cell responses

Also Published As

Publication number Publication date
DE60325967D1 (de) 2009-03-12
US7048922B2 (en) 2006-05-23
US20030223968A1 (en) 2003-12-04
EP1511515A1 (en) 2005-03-09
ES2321189T3 (es) 2009-06-03
EP2011863A1 (en) 2009-01-07
EP1511515B1 (en) 2009-01-21
US20050130303A1 (en) 2005-06-16
US20080292605A1 (en) 2008-11-27
WO2004056397A1 (en) 2004-07-08
JP2006514034A (ja) 2006-04-27
US7758857B2 (en) 2010-07-20

Similar Documents

Publication Publication Date Title
JP4863620B2 (ja) 抹消血単核細胞の培養方法及び該細胞を用いた薬剤組成物
Yamaguchi et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor.
CN102144028B (zh) 造血前体的扩增
US6849452B1 (en) Methods for activating natural killer (NK) cells and means for carrying out said methods
US20030124091A1 (en) Endothelial cell derived hematopoietic growth factor
JP2022526983A (ja) 凍結保存および細胞培養培地
JPH10510842A (ja) 造血細胞の増加方法
US7332158B2 (en) Compositions and treatments for myelosuppression by ex vivo activated immune cells
JPH04218365A (ja) 動物細胞増殖促進剤及び無血清培地
US6540994B1 (en) Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
US20060057121A1 (en) Compositions and treatments using ex vivo activated cells for myelosuppressed patients
CN101084001A (zh) 使用先体外后体内激活的细胞的组合物和疗法以用于骨髓抑制病人
CN114774355A (zh) 一种免疫细胞用无血清培养基
JP2008512454A (ja) 骨髄抑制患者に対する体外活性化細胞療法の構成と応用
McAdams The characterization of extracellularpH and medium osmolality as important parameters in the culture of human hematopoietic cells
JP2004536876A (ja) 造血促進物質としての骨再生組織増殖オリゴペプチド
van den Brink et al. Lak Cells and Autologous Bone Marrow Transplantation: Toward a Cure for Leukemia 1
IE64157B1 (en) Improvements in or relating to pharmaceutical compositions for the treatment of b-cell malignancies
Oldham Current concepts in immunology
CN105296420A (zh) 一种细胞培养液及其在培养巨核祖细胞中的应用
CHARAK et al. Augmentation of murine hematopoiesis by interleukin 2-activated irradiated T cells
JP2002080378A (ja) マクロファージを含む細胞製剤
MITA et al. HIGHLY PURIFIED MURINE INTERLEUKIN 5 (IL-5) STIMULATES EOSINOPHIL FUNCTION AND PROLONGS IN VITRO SURVIVAL
Kreutz et al. Induction of human monocyte to macrophage maturation in vitro by
Lee I 79f

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110913

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111011

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111108

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141118

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees